Cargando…
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
INTRODUCTION: Multiple myeloma (MM) is a relatively common and incurable hematological malignancy. Currently, there is no single standard therapy, with choice of treatment dependent on individual patient factors. Lenalidomide is an immunomodulatory drug with potent antitumor, antiangiogenic, immunom...
Autores principales: | Richardson, Paul, Mitsiades, Constantine, Laubach, Jacob, Schlossman, Robert, Ghobrial, Irene, Hideshima, Teru, Munshi, Nikhil, Anderson, Kenneth |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899783/ https://www.ncbi.nlm.nih.gov/pubmed/20694078 |
Ejemplares similares
-
The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010) -
Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009) -
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012) -
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*
por: Richardson, Paul G, et al.
Publicado: (2012) -
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)